Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionJohn W. Ostrominski, Muthiah Vaduganathan, Akshay S. Desai et al.|JACC Heart Failure|2023Cited by 39
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trialJohn W. Ostrominski, Scott D. Solomon, Muthiah Vaduganathan et al.|European Journal of Heart Failure|2022Cited by 32